Professor Brian MacCraith:

Depending on the scenario that emerges today from the European Medicines Agency, we were looking at mid-February for both scenarios but that could shift forwards or back by a week. There are other factors which might emerge today in terms of the dosage interval as well. All of these factors add to the uncertainty. Part of the work the task force is doing is to model through those very scenarios and then give advice to the various aspects of the structure the committee heard about earlier on. Perhaps Dr. Jessop can add a bit more-----